ライフサイエンスコーパス: extraprostatic

1 ul in identifying disease (1 prostate bed, 3 extraprostatic).

2 expressed prostatic secretions from men with extraprostatic and organ-confined prostate cancers ident

3 tivity than (18)F-FDG for intraprostatic and extraprostatic cancer detection.

4 nd 1994, 1369 non-stage A1 and 423 advanced (extraprostatic) cases of prostate cancer were diagnosed.

5 e cancer (excluding stage A1), 419 advanced (extraprostatic) cases, and 200 metastatic cases.

6 Patients with palpable extraprostatic disease (T3) have a poor prostate-specifi

7 between organ-confined tumors and those with extraprostatic disease extension.

8 rther, alternative modalities of determining extraprostatic disease must be investigated beyond the c

9 ate in the differentiation of prostatic from extraprostatic disease.

10 e of at least 7, or radiographic evidence of extraprostatic disease.

11 ivity of this pathway may be selected by the extraprostatic environment or, as supported by our data,

12 There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal v

13 predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicl

14 = 7 (P =.036 and P =.020, respectively) and extraprostatic extension (P =.047).

15 ession of the proliferation marker Ki-67 and extraprostatic extension of the tumor.

16 In the detection of extraprostatic extension of transition zone cancers, sen

17 (kappa = 0.266-0.439); and fair for definite extraprostatic extension on T2-weighted images (kappa =

18 was associated with cancers characterized by extraprostatic extension or distant metastases (stage C

19 Men with high-risk features (extraprostatic extension or high Gleason grade) face a h

20 ely selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, bu

21 vesicle invasion, positive surgical margins, extraprostatic extension) and salvage radiotherapy with

22 nical stage, Gleason score, surgical margin, extraprostatic extension, and seminal vesicle invasion,

23 reoperative prostate-specific antigen (PSA), extraprostatic extension, and total tumor volume.

24 in patients with either positive margins or extraprostatic extension, its effect on cause-specific m

25 ith pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or

26 thological features including Gleason score, extraprostatic extension, status of surgical margins, an

27 pecific antigen level greater than 10 ng/mL, extraprostatic extension, tumor volume more than 20%, ca

28 n the right lobe of the prostate without any extraprostatic extension.

29 imary Gleason 4 or any Gleason 5 disease, or extraprostatic extension.

30 gan-confined disease, and 20 (70%) of 30 had extraprostatic extension; 11 (37%) of the 30 had positiv

31 There were no incidental extraprostatic findings on PET suggestive of metastatic

32 state, including bed and seminal vesicle, or extraprostatic, including all lymph nodes, bone, or soft

33 Earlier detection of extraprostatic invasion and metastases by means of radio

34 .4%, and 70.3% for the lesion, prostate, and extraprostatic levels, respectively, with associated Fle

35 or recurrent disease in the prostate bed and extraprostatic locations.

36 l surface protein with limited expression in extraprostatic normal tissues.

37 ween the primary NE tumor and lesions in the extraprostatic organs.

38 In the detection of extraprostatic recurrence, anti-3-(18)F-FACBC had a sens

39 e region; and 83.3%, 75.0%, and 83.3% in the extraprostatic region for readers 1, 2, and 3, respectiv

40 Intra- and extraprostatic seed locations could be distinguished.

41 The most common extraprostatic site of seed implantation was the neurova

42 The most common extraprostatic tissue finding was increased signal inten

43 hibits only limited expression in benign and extraprostatic tissues, and thus represents an ideal tar

44 um and prostate cancer as well as in several extraprostatic tissues.

45 mental lineage, arising from either intra or extraprostatic tumour cell populations, at early and lat

46 h nodes originate from evolutionary advanced extraprostatic tumour cells rather than less advanced ce